Orforglipron
Oral GLP-1 Receptor Agonist
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
Laboratory and clinical investigations have examined its receptor-binding behavior and downstream metabolic signaling within controlled experimental frameworks.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
Orforglipron (LY3502970) is a non-peptide GLP-1 receptor agonist characterized for oral bioavailability — a property that distinguishes it from peptide-based incretin analogues that require injection. Research has focused on its selective activation of the GLP-1 receptor and the resulting effects on metabolic signaling pathways.
In controlled studies it has been evaluated for receptor pharmacology, glycemic regulation, and body-weight endpoints under structured experimental conditions.
Orforglipron emerged from medicinal-chemistry programs seeking small-molecule alternatives to peptide GLP-1 receptor agonists. Its non-peptide scaffold was designed to retain receptor agonism while enabling oral dosing.
Subsequent phase 1–3 clinical research has characterized its pharmacological profile in type 2 diabetes and obesity research populations.
Investigations into orforglipron focus on GLP-1 receptor activation models and incretin-pathway metabolic regulation. Research frameworks evaluate receptor-binding selectivity, glycemic endpoints, and body-weight outcomes under controlled clinical and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
GLP-1 receptor activation models
Addressed on this page by Rosenstock 2025, Wharton 2025, Sloop 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Rosenstock, J. et al. (2025) — Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- Wharton, S. et al. (2025) — Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- Sloop, KW. et al. (2024) — The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Incretin-pathway metabolic research
No paper cited on this page reports on incretin or metabolic. This heading marks where Orforglipron is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Oral small-molecule agonist pharmacology
Addressed on this page by Rosenstock 2025, Wharton 2025. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Rosenstock, J. et al. (2025) — Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- Wharton, S. et al. (2025) — Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Glycemic and body-weight endpoint studies
No paper cited on this page reports on glycemic, body or weight. This heading marks where Orforglipron is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2024 and 2025 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Orforglipron is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Orforglipron, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Orforglipron is also referred to as orfo, the oral GLP-1.
Orforglipron is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under GLP-1 receptor activation models, incretin-pathway metabolic research and oral small-molecule agonist pharmacology.
The 3 papers cited on this page, published between 2024 and 2025 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Orforglipron is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Orforglipron in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Orforglipron is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial (6mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of orforglipron. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
PubMedOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
PubMedThe pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
PubMedRelated
You May Also Like
Triple Receptor Agonist Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
From$79.99
Dual GLP-1 / GIP Research Peptide Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
From$39.99
GLP-1 Receptor Agonist Research Peptide Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
From$59.99
Amylin Receptor Research Peptide Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
From$99.99